|
 NetScientific's wholly-owned unit ProAxsis Ltd will look after
completing validation and global commercialisation of AstraZeneca's
SARS-CoV-2 serology ELISA and, in return, the Anglo-Swedish
drugmaker will receive a royalty fee on future global net sales of
the assay, the company said.
The ELISA, or enzyme-linked immunosorbent assay that is developed by
an internal research team at AstraZeneca, is a highly sensitive and
specific blood test that collects samples from a finger prick.
AstraZeneca said the test will be well-suited for antibody analyses
in large populations.
[to top of second column] |
 "The assay could, if fully
validated, potentially attract a substantial
market," NetScientific Chief Executive Officer
Ilian Iliev said in a statement.
NetScientific holds 95% stake in ProAxsis on a
fully diluted basis.
(Reporting by Vishwadha Chander in Bengaluru;
editing by Uttaresh.V)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
